PNMT Antibody (YA7151)

Phenylethanolamine N-methyltransferase (PNMT) is the terminal enzyme in the catecholamine biosynthetic pathway and catalyzes the methylation of norepinephrine to form epinephrine using S-adenosyl-L-methionine as the methyl donor^[1][2]. PNMT therefore serves as a key determinant of epinephrine production and contributes directly to the regulation of sympathoadrenal responses to physiological stress^[1][3]. Mechanistically, PNMT expression and activity are tightly controlled by hormonal and neural inputs, with glucocorticoids from the adrenal cortex providing a major regulatory signal that induces PNMT expression in adrenal medullary chromaffin cells^[3][4]. This adrenal glucocorticoid-PNMT axis supports stress-associated increases in epinephrine biosynthesis and represents a central mechanism linking endocrine and autonomic regulation^[3][4]. In disease-related research, genetic variation in PNMT has been associated with altered clinical phenotypes, including pain-related outcomes in sickle cell disease and susceptibility to early-onset Alzheimer disease, highlighting the importance of epinephrine biosynthesis in human pathophysiology^[5][6]. Compared with other methyltransferases involved in catecholamine metabolism, such as catechol-O-methyltransferase (COMT), PNMT performs the final biosynthetic step that generates biologically active epinephrine rather than catecholamine inactivation, making it functionally distinct within catecholamine pathways^[7]. For experimental applications, selective PNMT inhibitors have been widely used to reduce epinephrine synthesis and investigate adrenergic regulation in cardiovascular, neuroendocrine, and metabolic models^[7][8].